- Home
- VRDN vs ASTH Comparison
VRDN vs ASTH Comparison
Compare VRDN & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRDN | ASTH |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VRDN | ASTH |
|---|---|---|
| Price | $14.18 | $32.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $35.46 | $34.86 |
| AVG Volume (30 Days) | ★ 3.4M | 389.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.46 |
| Revenue | $5,706,000.00 | ★ $519,907,752.00 |
| Revenue This Year | $13.73 | $27.38 |
| Revenue Next Year | $279.00 | $10.78 |
| P/E Ratio | ★ N/A | $72.34 |
| Revenue Growth | N/A | ★ 45.90 |
| 52 Week Low | $11.76 | $18.08 |
| 52 Week High | $34.29 | $34.80 |
Technical Indicators
Market Signals| Indicator | VRDN | ASTH |
|---|---|---|
| Relative Strength Index (RSI) | 24.61 | 75.65 |
| Support Level | $13.59 | $28.59 |
| Resistance Level | $19.42 | $34.49 |
| Average True Range (ATR) | 1.00 | 1.41 |
| MACD | 0.22 | 0.49 |
| Stochastic Oscillator | 15.67 | 83.92 |
Price Performance
Historical ComparisonAbout VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
About ASTH Astrana Health Inc.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.